PubRank

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 28783719)

Published in Nature on August 02, 2017

Authors

Zhan Yao1, Rona Yaeger2, Vanessa S Rodrik-Outmezguine1, Anthony Tao3, Neilawattie M Torres1, Matthew T Chang4,5,6, Matthias Drosten7, Huiyong Zhao1, Fabiola Cecchi8, Todd Hembrough8, Judith Michels9,10, Hervé Baumert11, Linde Miles1,12, Naomi M Campbell13, Elisa de Stanchina1, David B Solit2,4,14, Mariano Barbacid7, Barry S Taylor4,5,14, Neal Rosen1,2,15

Author Affiliations

1: Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
2: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
3: Center for Neural Science, College of Arts and Sciences, New York University, New York, New York 10012, USA.
4: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
5: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
6: Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California 94158, USA.
7: Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández Almagro 3, Madrid 28029, Spain.
8: Molecular Oncology Group, NantOmics, LLC, 9600 Medical Center Drive, Suite 300, Rockville, Maryland 20854, USA.
9: Département de médecine oncologique, Gustave Roussy Cancer Campus, Villejuif, France.
10: Faculté de médecine, Université Paris Sud, Le Kremlin-Bicêtre, France.
11: Urology Department, Saint Joseph Hospital, Paris, France.
12: Anti-Cancer Drug Development Graduate Training Program, Department of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, Maryland 21205, USA.
13: Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
14: Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
15: Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

Articles citing this ↘

A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature (2017) 0.79

Cell signalling: Even kinase-inactive BRAF is oncogenic. Nat Rev Clin Oncol (2017) 0.75

Articles cited by this ↗

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res (2010) 4.70

Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell (2005) 4.24

Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn (2015) 3.84

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell (2015) 1.71

Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J (2010) 1.66

Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol (2015) 1.37

Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. J Mol Diagn (2013) 1.04

BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. Cancer Control (2014) 1.04

Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer (2015) 0.98

Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. Cancer Discov (2016) 0.98

Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One (2014) 0.94

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell (2016) 0.85

A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature (2017) 0.79